# A Phase I/II Study to Evaluate UC1010 Treatment in Premenstrual Dysphoric Disorder (PMDD)

> **NCT01875718** · PHASE1,PHASE2 · COMPLETED · sponsor: **Umecrine Mood AB** · enrollment: 146 (estimated)

## Conditions studied

- Premenstrual Dysphoric Disorder

## Interventions

- **DRUG:** UC1010
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01875718
- **Lead sponsor:** Umecrine Mood AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2015-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01875718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01875718, "A Phase I/II Study to Evaluate UC1010 Treatment in Premenstrual Dysphoric Disorder (PMDD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01875718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*